Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine (Nasdaq: CMND) has announced the publication of an international patent application for novel psychedelic-based compounds, developed in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent application focuses on innovative compounds designed to treat mental health disorders and addiction.
The announcement, made on April 08, 2025, represents a significant advancement in Clearmind's mission to develop next-generation psychedelic-derived therapeutics. These new '3.0 compounds' are designed to overcome limitations of classical psychedelics while providing safe and effective solutions for under-treated mental health conditions.
The patent is part of Clearmind's exclusive worldwide licensing agreement with Yissum, encompassing the development, research, manufacturing, marketing, and commercialization of products derived from patent-pending psychedelic compound synthesis.
Clearmind Medicine (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto internazionale per nuovi composti a base di psichedelici, sviluppati in collaborazione con Yissum Research Development Company dell'Università Ebraica di Gerusalemme. La domanda di brevetto si concentra su composti innovativi progettati per trattare disturbi mentali e dipendenze.
L'annuncio, fatto l'8 aprile 2025, rappresenta un significativo avanzamento nella missione di Clearmind di sviluppare terapie derivate da psichedelici di nuova generazione. Questi nuovi 'composti 3.0' sono progettati per superare le limitazioni degli psichedelici classici, offrendo soluzioni sicure ed efficaci per condizioni di salute mentale poco trattate.
Il brevetto fa parte dell'accordo di licenza esclusivo mondiale di Clearmind con Yissum, che comprende lo sviluppo, la ricerca, la produzione, il marketing e la commercializzazione di prodotti derivati dalla sintesi di composti psichedelici in attesa di brevetto.
Clearmind Medicine (Nasdaq: CMND) ha anunciado la publicación de una solicitud de patente internacional para nuevos compuestos basados en psicodélicos, desarrollados en colaboración con Yissum Research Development Company de la Universidad Hebrea de Jerusalén. La solicitud de patente se centra en compuestos innovadores diseñados para tratar trastornos de salud mental y adicciones.
El anuncio, realizado el 8 de abril de 2025, representa un avance significativo en la misión de Clearmind de desarrollar terapias derivadas de psicodélicos de nueva generación. Estos nuevos 'compuestos 3.0' están diseñados para superar las limitaciones de los psicodélicos clásicos, proporcionando soluciones seguras y efectivas para condiciones de salud mental poco tratadas.
La patente es parte del acuerdo de licencia exclusivo mundial de Clearmind con Yissum, que abarca el desarrollo, la investigación, la fabricación, el marketing y la comercialización de productos derivados de la síntesis de compuestos psicodélicos pendientes de patente.
클리어마인드 메디슨 (Nasdaq: CMND)은 예루살렘 히브리 대학교의 이썸 연구 개발 회사와 협력하여 개발된 새로운 환각 기반 화합물에 대한 국제 특허 출원을 발표했습니다. 이 특허 출원은 정신 건강 장애 및 중독 치료를 위해 설계된 혁신적인 화합물에 중점을 두고 있습니다.
2025년 4월 8일에 발표된 이 소식은 클리어마인드가 차세대 환각 유래 치료제를 개발하려는 사명의 중요한 진전을 나타냅니다. 이 새로운 '3.0 화합물'은 기존 환각제의 한계를 극복하고, 충분히 치료되지 않은 정신 건강 상태에 대한 안전하고 효과적인 솔루션을 제공하도록 설계되었습니다.
이 특허는 클리어마인드가 이썸과 체결한 독점 전 세계 라이센스 계약의 일환으로, 특허 출원 중인 환각 화합물 합성에서 파생된 제품의 개발, 연구, 제조, 마케팅 및 상용화를 포함합니다.
Clearmind Medicine (Nasdaq: CMND) a annoncé la publication d'une demande de brevet international pour de nouveaux composés à base de psychédéliques, développés en collaboration avec Yissum Research Development Company de l'Université hébraïque de Jérusalem. La demande de brevet se concentre sur des composés innovants conçus pour traiter les troubles de la santé mentale et les addictions.
L'annonce, faite le 8 avril 2025, représente une avancée significative dans la mission de Clearmind de développer des thérapies dérivées de psychédéliques de nouvelle génération. Ces nouveaux 'composés 3.0' sont conçus pour surmonter les limitations des psychédéliques classiques tout en offrant des solutions sûres et efficaces pour les conditions de santé mentale peu traitées.
Le brevet fait partie de l'accord de licence exclusif mondial de Clearmind avec Yissum, englobant le développement, la recherche, la fabrication, le marketing et la commercialisation de produits dérivés de la synthèse de composés psychédéliques en attente de brevet.
Clearmind Medicine (Nasdaq: CMND) hat die Veröffentlichung eines internationalen Patentantrags für neuartige psychedelisch basierte Verbindungen bekannt gegeben, die in Zusammenarbeit mit der Yissum Research Development Company der Hebräischen Universität Jerusalem entwickelt wurden. Der Patentantrag konzentriert sich auf innovative Verbindungen, die zur Behandlung von psychischen Erkrankungen und Sucht entwickelt wurden.
Die Ankündigung, die am 8. April 2025 gemacht wurde, stellt einen bedeutenden Fortschritt in Clearminds Mission dar, Therapien der nächsten Generation auf Basis von Psychedelika zu entwickeln. Diese neuen '3.0 Verbindungen' sind darauf ausgelegt, die Einschränkungen klassischer Psychedelika zu überwinden und sichere sowie effektive Lösungen für unterbehandelte psychische Erkrankungen zu bieten.
Das Patent ist Teil des exklusiven weltweiten Lizenzvertrags von Clearmind mit Yissum, der die Entwicklung, Forschung, Herstellung, Vermarktung und Kommerzialisierung von Produkten umfasst, die aus der Patentanmeldung zur Synthese psychedelischer Verbindungen hervorgehen.
- None.
- None.
Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The patent application covers innovative psychedelic-based compounds designed for the treatment of mental health disorders and addiction.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “The publication highlights the potential of our collaboration with Yissum in our mission to transform mental health treatment through next-generation psychedelic-based therapeutics. Our collaboration with Yissum has yielded highly innovative compounds that go beyond the limitations of classical psychedelics. These new 3.0 compounds reflect our ongoing efforts to advancing safe, effective and scalable solutions for some of the most challenging and under-treated mental health and addiction disorders.”
The patent is part of Clearmind’s exclusive worldwide licensing agreement with Yissum to develop, research, manufacture, market and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of its collaboration with Yissum in its mission to transform mental health treatment through next-generation psychedelic-based therapeutics and its ongoing efforts to advancing safe, effective and scalable solutions for some of the most challenging and under-treated mental health and addiction disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the purpose of Clearmind Medicine's (CMND) new patent application?
When did Clearmind Medicine (CMND) announce their new patent application?
What is unique about Clearmind's (CMND) new psychedelic compounds?
What rights does the licensing agreement give Clearmind Medicine (CMND)?
